Switzerland· 68276001
Bortezomib Accord liquid
A bortezomib product containing bortezomibum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Bortezomib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01XG01 (bortezomib), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Bortezomib · ATC L01XG01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of bortezomib costs, country by country.
Normalised to the WHO defined daily dose (0.45 mg), so markets compare like for like.
- Switzerland: $66.46 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Bortezomib · price per daily dose (0.45 mg)
USD · FX 28 Sept 2026
- CH Switzerland$66.46
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- bortezomibum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L01XG01
- ATC class
- Bortezomib
- Defined daily dose
- 0.45 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680682760015Durchstf 1 StkCHF 311.1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
587 interactions on record for bortezomib.
Graded by severity as the source publishes them — 45 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bortezomib · interactions on record
587 records
- 45 severe
- 250 moderate
- 66 minor
- 226 info
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- RifampicinJ04AB02severe
- RifabutinJ04AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Bortezomib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBORTEZOMIB ACCORDAccord Healthcare S.L.U., Barcelona
- SpainBORTEZOMIB ACCORD 2,5 MG/ML SOLUCION INYECTABLEAccord Healthcare S.L.U.
- SwedenBortezomib Accord 2,5 mg/ml Injektionsvätska, lösningAccord Healthcare S.L.U.
- IcelandBortezomib AccordAccord Healthcare S.L.U.
- BelgiumBortezomib Ever Pharma 2.5 mg/mlEVER Valinject
- NorwayBortezomib AccordAccord Healthcare S.L.U.
- PolandBortezomib AccordAccord Healthcare S.L.U.
- GermanyBortezomibNovumgen Limited
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Abormib, Bortezomib Ever Pharma
- Belgium · Bortezomib Eg, Bortezomib Eugia
- Bulgaria · Bortezomib Ever Pharma, Бортезомиб Актавис
- Cyprus · Bortezomib Pharmazac, Bortezomib Stada
- Czechia · Bortezomib Ever Pharma, Bortezomib Msn
- Germany · Bortezomib, Bortezomib Amarox
- Denmark · Bortezomib Actavis, Bortezomib Ever Pharma
- Spain · Bortezomib Aurovitas, Bortezomib Combix
- Finland · Bortezomib Avansor, Bortezomib Ever Pharma
- France · Bortezomib, Bortezomib Arrow
- United Kingdom (Northern Ireland) · Bortezomib, Bortezomib Accord
- Greece · Bortezomib Pharmazac, Bortezomib Sandoz
- Croatia · Bortezomib Alpha-Medical, Bortezomib Ever Pharma
- Hungary · Bortezomib Ever Pharma, Bortezomib Msn
- Ireland · Bortezomib Aspire Pharma (Malta), Bortezomib Biotech Pharma Limited
- Iceland · Bortezomib Accord, Bortezomib Actavis
- Italy · Bortezomib Aurobindo, Bortezomib Dr. Reddy’s
- Liechtenstein · Bortezomib Accord, Bortezomib Fresenius Kabi
- Luxembourg · Bortezomib Eg
- Latvia · Bortezomib Tzf
- Malta · Bortezomib Clonmel, Bortezomib Dr. Reddy’s
- Netherlands · Bortezomib Amarox, Bortezomib Cf
- Norway · Bortezomib Accord, Bortezomib Ever Pharma
- Poland · Adabonib, Bortezomib Eugia
- Portugal · Bortezomib Ever Pharma, Bortezomib Extrovis
- Romania · Bortezomib, Bortezomib Dr. Reddy’s
- Sweden · Bortezomib Avansor, Bortezomib Ever Pharma
- Slovenia · Bortezomib Actavis, Bortezomib Ever Pharma
- Slovakia · Bortezomib Ever Pharma, Bortezomib Glenmark
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b29058c2-8889-445a-ae44-54b323c33e71 GET /v1/drugs/b29058c2-8889-445a-ae44-54b323c33e71?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "bortezomibum 2.5 mg",
"valid_from": "2022-02-01",
"limitations": "[{\"description\":\"<b>Austausch Originalpräparat/Generikum</b><br>\\nFür die Behandlung mit BORTEZOMIB ACCORD LIQUID ist keine neue Kostengutsprache nötig, wenn in derselben Indikation bereits eine Kostengutsprache für das Originalpräparat oder ein anderes Generikum besteht. <br>\\n<br>\\nZur Induktionsbehandlung in Kombination mit Standardchemotherapie vor Stammzelltransplantation bei erwachsenen Patienten mit multiplem Myelom.<br>\\nIn Kombination mit Melphalan und Prednison bei bisher unbehandelten Patienten mit multiplem Myelom.<br>\\nZur Behandlung von Patienten mit rezidivierendem/refraktärem multiplem Myelom, welche mindestens eine vorhergehende Therapie erhielten.<br>\\nDie Therapien bedürfen der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2024-10-01\",\"validTo\":null}]",
"galenic_form": "Inj Lös 2.5 mg/ml",
"therapeutic_area": null,
"sl_inclusion_date": "2022-02-01",
"self_retention_pct": 10
}See everything about bortezomib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.